Por favor, use este identificador para citar o enlazar a este item: http://hdl.handle.net/10261/245369
COMPARTIR / EXPORTAR:
logo share SHARE logo core CORE BASE
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE

Invitar a revisión por pares abierta
Título

Spatio-temporal tumor heterogeneity in metastatic CRC tumors: A mutational-based approach

AutorCarmen, Sofía del; Sayagués, José María CSIC ORCID ; Bengoechea, Óscar; Anduaga, María Fernanda; Alcazar, Jose Antonio; Gervas, Ruth; García, Jacinto; Orfao, Alberto CSIC ORCID ; Muñoz-Bellvis, Luís; Sarasquete, María Eugenia; Abad, María del Mar
Palabras claveColorectal cancer
Clonal evolution
Anti-EGFR
Mutational profiles
Tumor heterogeneity
Fecha de publicación28-sep-2018
EditorImpact Journals
CitaciónOncotarget 9(76): 34279-34288 (2018)
ResumenIt is well known that activating mutations in the KRAS and NRAS genes are associated with poor response to anti-EGFR therapies in patients with metastatic colorectal cancer (mCRC). Approximately half of the patients with wild-type (WT) KRAS colorectal carcinoma do not respond to these therapies. This could be because the treatment decision is determined by the mutational profile of the primary tumor, regardless of the presence of small tumor subclones harboring RAS mutations in lymph nodes or liver metastases. We analyzed the mutational profile of the KRAS, NRAS, BRAF and PI3KCA genes using low-density microarray technology in samples of 26 paired primary tumors, 16 lymph nodes and 34 liver metastases from 26 untreated mCRC patients (n=76 samples). The most frequent mutations found in primary tumors were KRAS (15%) and PI3KCA (15%), followed by NRAS (8%) and BRAF (4%). The distribution of the mutations in the 16 lymph node metastases analyzed was as follows: 4 (25%) in KRAS gene, 3 (19%) in NRAS gene and 1 mutation each in PI3KCA and BRAF genes (6%). As expected, the most prevalent mutation in liver metastasis was in the KRAS gene (35%), followed by PI3KCA (9%) and BRAF (6%). Of the 26 cases studied, 15 (58%) displayed an overall concordance in the mutation status detected in the lymph node metastases and liver metastases compared with primary tumor, suggesting no clonal evolution. In contrast, the mutation profiles differed in the primary tumor and lymph node/metastases samples of the remaining 11 patients (48%), suggesting a spatial and temporal clonal evolution. We confirm the presence of different mutational profiles among primary tumors, lymph node metastases and liver metastases. Our results suggest the need to perform mutational analysis in all available tumor samples of patients before deciding to commence anti-EGFR treatment.
Versión del editorhttps://doi.org/10.18632/oncotarget.26081
URIhttp://hdl.handle.net/10261/245369
DOI10.18632/oncotarget.26081
E-ISSN1949-2553
Aparece en las colecciones: (IBMCC) Artículos




Ficheros en este ítem:
Fichero Descripción Tamaño Formato
Spatio_Carmen_PV_Art2018.pdf5,81 MBAdobe PDFVista previa
Visualizar/Abrir
Mostrar el registro completo

CORE Recommender

PubMed Central
Citations

11
checked on 02-mar-2024

SCOPUSTM   
Citations

18
checked on 23-mar-2024

Page view(s)

60
checked on 28-mar-2024

Download(s)

25
checked on 28-mar-2024

Google ScholarTM

Check

Altmetric

Altmetric


Artículos relacionados:


Este item está licenciado bajo una Licencia Creative Commons Creative Commons